TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Patients after surgical removal of histologically confirmed World Health Organization high-grade gliomas, including astrocytomas grade III (anaplastic astrocytoma), astrocytoma grade IV (glioblastoma multiforme, GBM), anaplastic oligodendroglioma and oligoastrocytoma~* Karnofsky performance status of greater or equal 60~* Patients who signed informed consent~* Patients can be receiving standard or investigational chemotherapy , hormonal therapy, immunotherapy or biologic agents as the primary treatment for their tumor~* Glucocorticoid therapy is allowed~* Bone marrow function (absolute neutrophil count \[ANC\] \>=1500/mm\^3 and platelet count \>=75,000/mm\^3); in the event of plate count dropping below 50,000/ mm\^3 the Boswellia will be withdrawn until plate count reaches 75,000 mm\^3 and above~* Liver function (bilirubin and alkaline phosphatase =\< 2 x normal and serum glutamic oxaloacetic transaminase \[SGOT\] =\< 3 x normal)~* Renal function (blood urea nitrogen \[BUN\] or creatinine =\< 1.5 x normal)~* Patients suffering from mild to moderate asthma, liver and kidney disease; an assessment of the condition will be made to establish a baseline and monitor progress at 4 weekly intervals to start with for the first two months and thereafter at the usual study intervals of 4 and 6 months; if there is any significant deterioration in their condition the Boswellia will be withdrawn until these parameters are restored to their pre-treatment levels~EXCLUSION CRITERIA:~* Any medical condition that could interfere with eating and oral administration of B. serrata~* Patients already taking herbal preparations that contain 5-LO inhibitors~* Any previous (within the past 3 years) or concurrent malignancies at other sites, with the exception of surgically cured carcinoma-in-situ of the cervix and non-melanoma skin cancer~* Pregnancy and breastfeeding~* Active infection~* Inability to be followed closely at the Cleveland Clinic Foundation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (intervention) (Type: EXPERIMENTAL): Patients receive oral Boswellia serrata extract 4 times a day and oral cyanocobalamin (vitamin B 12) once a day for 6 months in the absence of unacceptable toxicity.
- Arm II (control) (Type: ACTIVE_COMPARATOR): Patients in the control arm receive oral cyanocobalamin (vitamin B 12) once a day for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Respiratory failure requiring mechanical ventilation due to COVID-19 induced pneumonia with confirmation via SARS-CoV-2 RT-PCR testing~* PaO2/FiO2 ratio \< 300 (or SpO2/FiO2 \< 315)~* Bilateral pulmonary infiltrates~Exclusion Criteria:~* Contraindication to transfusion (severe volume overload, history of anaphylaxis to blood products).~* In the opinion of the site investigator or primary clinical care team, anticipated to die within 48 hours.~* Acute or chronic disease/illness that, in the opinion of the site investigator, has an expected life expectancy of less than 28 days unrelated to COVID-19 induced pneumonia (e.g.; stage IV malignancy, neurodegenerative disease, anoxic brain injury, etc.)~* Use of home oxygen at baseline~* Use of home mechanical ventilation at baseline (CPAP or BIPAP without need for oxygen is NOT an exclusion)~* Respiratory failure caused by illness other than SARS-CoV-2~* Other documented uncontrolled infection.~* More than 72 hours have elapsed since first meeting inclusion criteria~* Severe DIC, TTP, or antithrombin III deficiency needing factor replacement, FFP, cryoprecipitate.~* Patient is on Warfarin and it is deemed necessary to maintain therapeutic INR (because the CP will reverse the warfarin effect).~* On dialysis at the time enrollment is considered.~* Active intracranial bleeding.~* Clinically significant myocardial ischemia.~* Prisoner or Incarceration~* Pregnancy or active breast feeding~* Has already received convalescent plasma for COVID-19 infection during current admission~* Current participation in another interventional research study~* Inability or unwillingness of subject or legal surrogate/representative to give written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intubated COVID-19 patients in the ICU (Type: EXPERIMENTAL): Mechanically ventilated intubated patients with respiratory failure due to COVID-19

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Nitroglycerin in Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Non-small cell lung cancer stage IB-IV amenable for radiotherapy with curative intent.~* (Stage IV patients with oligometastic (1-4 metastases) NSCLC are regularly treated radically in the IKNL region).~* Patients not included in the PET-Boost or the Lucanix trial.~* WHO performance status 0-2.~* Willing and able to comply with the study prescriptions.~* 18 years or older.~* Ability to give and having given written informed consent before patient registration.~* No recent (\< 3 months) severe cardiac disease (NYHA class \>1) (congestive heart failure, infarction).~* No radiotherapy in 4 weeks prior to this study.~* No treatment with investigational drugs in 4 weeks prior to or during this study.~* No known allergy to nitroglycerin or nitroglycerin patch.~* No known allergy to iodine based contrast agents~* No use of Levitra, Viagra or Cialis at the time of application of the nitroglycerin patch.~* No conditions necessitating the use of ergot alkaloids, alpha blockers (eg tamsulosine), betablockers or calcium channel blockers on the day of nitroglycerin patch application).~* No other active malignancy.~* No major surgery (excluding diagnostic procedures like eg mediastinoscopy) in previous 4 weeks.~* Adequate renal function: calculated creatinine clearance at least 60ml/min.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nitroglycerin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Phrenic Nerve Stimulation During Swallowing : Experimental Model of Aspiration

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~stroke with aspiration~Exclusion Criteria:~obstructive rhinitis bronchial obstruction pace maker phrenic nerve paralysis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Recurrent ovarian, fallopian tube, or primary peritoneal carcinoma. Histologic or cytologic confirmation of the original primary tumor is required.~* Must have measurable disease which is defined as at least one lesion that can be accurately measured in at least one dimension. Each lesion must be \>20mm when measured by conventional techniques.~* Must have at least one target lesion to be used to assess response.~* Platinum-sensitive tumors, defined as a platinum free interval of at least 6 months, and may have had up to two prior treatment regimens.~* Eastern Cooperative Oncology Group score of 0 or 1~* Life expectancy of 12 weeks or longer~* 18 years of age or older~* Adequate bone marrow, renal, neurologic and liver function~* Normal blood coagulation parameters~Exclusion Criteria:~* Chemotherapy within last 3 weeks~* Current, recent (within 4 weeks), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study.~* Known bleeding disorder or coagulopathy, or history of stroke.~* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study entry or the anticipation of need for major surgical procedure during the course of the study.~* Minor surgical procedures within 14 days of study entry.~* Significant cardiovascular disease, New York Heart Association Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, a history of deep vein thrombosis, or Grade II or greater, clinically significant peripheral vascular disease within 1 year of study entry.~* Urine protein:creatinine ration greater than or equal to 1.0~* History or clinical evidence of central nervous system disease~* Patients with other invasive malignancies, with the exception of non-melanoma skin cancer, who have evidence of disease within last three years.~* More than 2 prior lines of chemotherapy~* Previous treatment with a VEGF targeted inhibitor or antibody~* Serious non-healing wound, ulcer or bone fracture~* Prior radiation therapy to more than one-third of hematopoietic sites.~* History of abdominal fistulas, gastrointestinal perforation, intra-abdominal abscess, or partial bowel obstruction within 6 months~* Pregnant or lactating

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy (Type: EXPERIMENTAL): All patients received oxaliplatin, gemcitabine, and bevacizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of PDE-5 Inhibition on Postprandial Hyperglycemia in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Postmenopausal state, defines as natural amenorrhea for at least 12 months.~2. Age; females 52-65 years, males: 40-65 years.~3. Type 2 diabetes based on fasting plasma glucose or 2-hr glucose after an OGTT.~4. Diabetes duration less than 5 years.~Exclusion Criteria:~1. Patients with concurrent use of nitrates or NO donors, history of heart or cerebrovascular disease, cardiac failure (stages NYHA II-IV), uncontrolled hypertension (\> 160/100 mm Hg), significant diabetic complications, and inadequate glycemic control (HbA1c \> 7%, ref value 3.5-5.3%)~2. Patients on glitazones, insulin, beta-blockers, ACE-inhibitors and corticosteroids

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): A single dose of placebo is administered 30 min before a mixed meal.
- Tadalafil (Type: ACTIVE_COMPARATOR): A single dose of tadalafil 20 mg is administered 30 min before a mixed meal.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating MMPs in Burns

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Admitted with acute burns injuries (flame, contact or scald) requiring at least one surgical excision and grafting operation will be considered for inclusion~* Burn injury less than one week old~Exclusion Criteria:~* Electrical, chemical or cold-induced burn injury~* Total body surface area burn \>50 %~* Pre injury diagnosis of chronic renal insufficiency, liver failure, refusal to accept blood transfusion or withdrawal of care within three days of admission will also be exclusion criteria~* Patients not expected to survive~* Patients presenting with re-injury to previously burned and treated areas.~* Patients who present after receiving burn excision surgery out an outside facility for the current acute injury

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 98 Years
- Healthy Volunteers: f

Study Arms:
- Patients admitted to the burn center (Type: None): Patients admitted to the Burn Service with acute burn injuries requiring at least one surgical excision and grafting operation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating IV Oncaspar® and IV Gemzar® in the Treatment of Solid Tumors and Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Capable of understanding the protocol requirements and risks and providing written informed consent.~* Histologically or cytologically confirmed diagnosis of advanced and/or metastatic solid tumor or lymphoma (Hodgkin's or non-Hodgkin's), and have either failed primary treatment or there is no available standard treatment.~* Prior standard therapy was not effective, or no known therapy will extend survival or provide benefit.~* Measurable or evaluable disease.~* Age 18 years or older.~* Score of 0-2 on the Eastern Cooperative Oncology Group (ECOG) performance scale.~* Absolute neutrophil count (ANC)≥ 1500/μL.~* Platelet count ≥ 100,000/μL.~* Hemoglobin ≥ 9.0 g/dL.~* Fibrinogen ≥ 0.75x the lower limit of normal (LLN), and PT, PTT, and INR ≤ 1.5x the upper limit of normal (ULN).~* Serum creatinine ≤ 1.5 mg/dL or creatinine clearance ≥ 60 mL/min.~* Total bilirubin ≤ 1.5 mg/dL.~* Transaminases (AST, ALT) ≤ 2.5x the upper limit of normal (ULN) (may be ≤ 5.0x ULN if due to metastatic disease in the liver).~* Amylase and lipase levels are within normal limits.~Any subject who has given informed consent to participate in the clinical study and who meets all entry criteria for the study may participate in the tumor analysis part of the study.~Exclusion Criteria:~* Subjects meeting any of the following exclusion criteria will not be eligible for enrollment.~* Concurrent serious medical illness that could potentially interfere with protocol compliance.~* Has pancreatitis or a history of pancreatitis, not related to pancreatic cancer.~* Has a coagulopathy or a history of coagulopathy.~* Known chronic infectious disease, such as AIDS or hepatitis (screening for hepatitis and HIV will not be performed).~* Positive screening pregnancy test or is breast-feeding.~* Female or male subject of reproductive capacity unwilling to use methods appropriate to prevent pregnancy during the course of this protocol.~* Known or clinically suspected active brain metastases.~* Received pegaspargase (Oncaspar®, PEG-L-asparaginase) or any asparaginase or asparaginase-containing drug, at any time prior to this study.~* Received prior chemotherapy, immunotherapy or an investigational agent regimen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Determination of Specific Biomarkers of Acute Attack of Angioedema Within Pediatric Population

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~For HAE: patient with a documented diagnosis of HAE:~* type I (from an antigenic deficiency of the C1 esterase inhibitor) or type II (from a functional deficiency of the C1 esterase inhibitor). The existence of a mutation in SERPING1 was not necessary for the inclusion~* HAE with normal C1-INH (ex type III) with a required mutation in FXII gene or with a typical family history of HAE diagnosed by a specialized physician belonging to CREAK network.~For AE resulting of mast cell activation: a documented diagnosis of AE resulting of mast cell activation included:~* mastocytosis,~* chronic spontaneous urticaria,~* acute urticaria after exposure of allergen during allergy challenge tests,~* mast cell activation syndrome.~For the control group:~* composed of patients who presented a stabilized disease (that was not infectious, not auto-inflammatory or inflammatory disease and without implication of endothelial cells).~Exclusion Criteria:~* Over 18 years or under 1 year.~* Diagnosis of HAE with a normal C1 esterase inhibitor or AE of unknown aetiology.~* Patients with HAE who received an acute attack treatment before the blood sample (the C1 esterase inhibitor concentrate or a bradykinin B2 receptor antagonist); patients with HAE who received a prophylactic treatment (danazol).~* Patients who were treated by omalizumab or corticosteroid treatment.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- patients with hereditary angioedema (Type: None): A blood sample will be performed in crisis and 7 days after the crisis.
- patients with angioedema resulting of mast cell activation (Type: None): A blood sample will be performed in crisis and 7 days after the crisis.
- healthy patients, without angioedema (Type: None): A quantity of additional blood was taken from eligible patients who had a scheduled blood sample.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hypoxia-inducible Factor-1 (HIF-1) Regulated Circulating Angiogenic Cells (CACs) Recruitment in Burn Wound Healing

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Recruitment of patients at the Johns Hopkins Regional Burn Center for study will be based upon the following clinical criteria:~* Second degree scald burn of 10 cm2~* Age between 14 to 75 years~* Burn area equal or less than 95% of Burn Surface Area (BSA)~* Body temperature between 98.5 and 101 degree F~* Informed consent for enrolment into study~* Spanish speaking patients will be included when we have a Spanish consent form available.~Exclusion Criteria:~* First and third degree burn wounds~* Hemodynamic instability (SBP below 100, Heart Rate (HR) over 100, urine output less than 30 ml/hour~* Area of burn over 20% of BSA~* Hypothermia T\<98.5 or Hyperthermia T\>101 degree F~* Urine output less than 30 ml/hour~* Serum albumin less than 3 mg/ml.~* Subjects weighing less than 50 kg.

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Healthy volunteers (Type: SHAM_COMPARATOR): Healthy volunteers with no burn wounds Volunteers donate blood that will be studied in comparison to patients who have sustained burns. The circulating bone marrow stem cells will be counted and compared to the levels in burn patients. Six 12 ml tubes will be taken for the study. You will not be compensated. But you will be helping to advance science if you join the study.
- Burn volunteer (Type: ACTIVE_COMPARATOR): To recruit burn wound patients with defined clinical criteria for study. A second-degree burn of at least 10 cm2 to up to 95% BSA; age = 14-75 years; BP \> 100 mm Hg systolic; heart rate \< 100 beats/minute; urine output \> 30 ml/hour; area of burn \< 20% of BSA; body temperature = 98.5-101 degrees Fahrenheit; serum albumin \> 3 mg/ml; and informed consent. We will also obtain a history regarding the presence or absence of risk factors that may affect CAC numbers: hypertension \> 1 year; smoking \> 2 pack-years or within the last year; diabetes mellitus; and family history of premature coronary artery disease (men \< 55 and women \< 65 years of age).Six 12 ml tubes will be taken at 5 time points

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Cutaneous Leishmaniasis With a Combination of Miltefosine and Antimony

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Parasitological confirmation~* at least 1 lesion must be ulcerative~* No specific antileishmanial therapy during the previous six months~Exclusion Criteria:~* Concomitant diseases such as Tuberculosis, HIV, diabetes, renal failure, liver disease~* abnormalities CTC 2 in blood, liver, kidney test or EKG

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Miltefosine and Antimony (Type: EXPERIMENTAL): Miltefosine 1,5 to 2,5 mg x k x d during 14 days simultaneously with meglumine antimoniate 20 mg x kg x d during 10 days
- Miltefosine alone (Type: ACTIVE_COMPARATOR): Miltefosine 1,5 to 2,5 mg x kg x d during 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy